Journal
CANCER LETTERS
Volume 280, Issue 2, Pages 233-241Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.02.019
Keywords
Panobinostat; LBH589; Histone deacetylase inhibitors; Pharmacodynamics; Hematologic malignancies; Solid tumors
Categories
Ask authors/readers for more resources
The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and nonhistone cellular proteins. The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition of all HDAC enzymes implicated in cancer and has demonstrated potent anti-tumor activity in preclinical models and promising clinical efficacy in cancer patients. In this review we discuss the successes and challenges surrounding the development of panobinostat, focusing on its proposed mechanism of action, preclinical anti-tumor activity, and early clinical efficacy in hematologic and solid tumors. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available